High‐dose corticosteroid use and risk of hospitalization for infection in patients treated with immune checkpoint inhibitors––A nationwide register‐based cohort study
Authors:
Open Access
- 8 June 2021
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 10 (14) , 4957-4963
Abstract
High‐dose corticosteroids have been associated with increased risk of serious infection in patients with metastatic melanoma treated with immune checkpoint inhibitors targeting cytotoxic T‐lymphocyte antigen 4. This potential association needs to be examined further among patients with other cancer types and for other immune checkpoint inhibitors. We examined whether receipt of high‐dose corticosteroids was associated with increased rates of hospitalization for infection among 981 Danish renal, urothelial, and lung cancer patients followed from first administration of programmed death receptor 1 (PD‐1)/programmed death ligand 1 (PD‐L1) immune checkpoint inhibitors. Our cohort analysis was based on the information from national medical registries. During follow‐up, 522 patients (53.2%) initiated treatment with high‐dose corticosteroids and 317 patients (32.3%) experienced at least one hospitalization for infection. In analyses adjusted for age, sex, and previous use of chemotherapy/targeted therapy, initiation of high‐dose systemic corticosteroids was associated with increased rate of hospitalization for infections (hazard ratio (HR) = 2.96, 95% confidence interval (CI) = 2.41–3.65) even in patients not receiving any chemotherapy/targeted therapy (HR = 3.66, 95% CI = 2.25–5.96). Our findings showed that high‐dose corticosteroid initiation is associated with hospitalization for infection in patients treated with PD‐1/PD‐L1 immune checkpoint inhibitors. Clinicians and patients should be aware of this risk of infection when initiating treatment with high‐dose corticosteroids.Keywords
Funding Information
- Merck KGaA
This publication has 16 references indexed in Scilit:
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice GuidelineJournal of Clinical Oncology, 2018
- Immune-Related Adverse Events Associated with Immune Checkpoint BlockadeNew England Journal of Medicine, 2018
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2017
- Data Resource Profile: The Danish National Prescription RegistryInternational Journal of Epidemiology, 2016
- The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of MelanomaClinical Infectious Diseases, 2016
- The Danish National Patient Registry: a review of content, data quality, and research potentialClinical Epidemiology, 2015
- Positive predictive value of primary inpatient discharge diagnoses of infection among cancer patients in the Danish National Registry of PatientsAnnals of Epidemiology, 2014
- AJCC Cancer Staging Atlas2012
- The Danish Cancer RegistryScandinavian Journal of Public Health, 2011
- Cox's Regression Model for Counting Processes: A Large Sample StudyThe Annals of Statistics, 1982